Treatment of complicated intra-abdominal infections in the era of multi-drug resistant bacteria

European Journal of Medical Research

W Uhl¹  AM Chromik¹  T Herzog¹ 

[1] Department of Surgery, St. Josef Hospital, Ruhr University Bochum, Germany

关键词: intra-abdominal infection;    multi-drug resistance;    antibiotic treatment;   

Others  :  829370
DOI  :  10.1186/2047-783X-15-12-525

 received in 2010-11-14, accepted in 2010-11-15,  发布年份 2010

【 摘 要 】

The management of severe intra-abdominal infections remains a major challenge facing surgeons and intensive care physicians, because of its association with high morbidity and mortality. Surgical management and intensive care medicine have constantly improved, but in the recent years a rapidly continuing emergence of resistant pathogens led to treatment failure secondary to infections with multi-drug resistant bacteria. In secondary peritonitis the rate of resistant germs at the initial operation is already 30%. The lack of effective antibiotics against these pathogens resulted in the development of new broad-spectrum compounds and antibiotics directed against resistant germs. But so far no "super-drug" with efficacy against all resistant bacteria exists. Even more, soon after their approval, reports on resistance against these novel drugs have been reported, or the drugs were withdrawn from the market due to severe side effects. Since pharmaceutical companies reduced their investigations on antibiotic research, only few new antimicrobial derivates are available.

In abdominal surgery you may be in fear that in the future more and more patients with tertiary peritonitis secondary to multi-drug resistant species are seen with an increase of mortality after secondary peritonitis.

This article reviews the current treatment modalities for complicated intra-abdominal infections with special reference to the antibiotic treatment of complicated intra-abdominal infections with multi-drug resistant species.

【 授权许可】

   
2010 I. Holzapfel Publishers

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Barie PS, Hydo LJ, Eachempati SR: Longitudinal outcomes of intra-abdominal infection complicated by critical illness. Surg Infect (Larchmt) 2004, 5(4):365-73.
• [2]Dellinger EP, Wertz MJ, Meakins JL, et al.: Surgical infection stratification system for intra-abdominal infection. Multicenter trial. Arch Surg 1985, 120(1):21-9.
• [3]Finfer S, Bellomo R, Lipman J, et al.: Adult-population incidence of severe sepsis in Australian and New Zealand intensive care units. Intensive Care Med 2004, 30(4):589-96.
• [4]Vincent JL, Rello J, Marshall J, et al.: International study of the prevalence and outcomes of infection in intensive care units. Jama 2009, 302(21):2323-9.
• [5]Wittmann DH, Schein M, Condon RE: Management of secondary peritonitis. Ann Surg 1996, 224(1):10-8.
• [6]Myers E, Hurley M, O'Sullivan GC, et al.: Laparoscopic peritoneal lavage for generalized peritonitis due to perforated diverticulitis. Br J Surg 2008, 95(1):97-101.
• [7]Penninckx FM, Kerremans RP, Lauwers PM: Planned re-laparotomies in the surgical treatment of severe generalized peritonitis from intestinal origin. World J Surg 1983, 7(6):762-6.
• [8]Teichmann W, Wittmann DH, Andreone PA: Scheduled reoperations (etappenlavage) for diffuse peritonitis. Arch Surg 1986, 121(2):147-52.
• [9]Solomkin JS, Mazuski JE, Bradley JS, et al.: Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Surg Infect (Larchmt) 2010, 11(1):79-109.
• [10]Ingraham AM, Cohen ME, Bilimoria KY, et al.: Comparison of outcomes after laparoscopic versus open appendectomy for acute appendicitis at 222 ACS NSQIP hospitals. Surgery 2010, 148(4):625-35. discussion 635-7
• [11]Farthmann EH, Schoffel U: Epidemiology and patho-physiology of intraabdominal infections (IAI). Infection 1998, 26(5):329-34.
• [12]Calandra T, Cohen J: The international sepsis forum consensus conference on definitions of infection in the intensive care unit. Crit Care Med 2005, 33(7):1538-48.
• [13]Fridkin SK, Hageman JC, Morrison M, et al.: Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med 2005, 352(14):1436-44.
• [14]Montravers P, Lepape A, Dubreuil L, et al.: Clinical and microbiological profiles of community-acquired and nosocomial intra-abdominal infections: results of the French prospective, observational EBIIA study. J Antimicrob Chemother 2009, 63(4):785-94.
• [15]Evans HL, Raymond DP, Pelletier SJ, et al.: Diagnosis of intra-abdominal infection in the critically ill patient. Curr Opin Crit Care 2001, 7(2):117-21.
• [16]Reemst PH, van Goor H, Goris RJ: SIRS, MODS and tertiary peritonitis. Eur J Surg Suppl 1996, 576:47-8. discussion 49
• [17]Nathens AB, Rotstein OD, Marshall JC: Tertiary peritonitis: clinical features of a complex nosocomial infection. World J Surg 1998, 22(2):158-63.
• [18]Chromik AM, Meiser A, Holling J, et al.: Identification of patients at risk for development of tertiary peritonitis on a surgical intensive care unit. J Gastrointest Surg 2009, 13(7):1358-67.
• [19]Menichetti F, Sganga G: Definition and classification of intra-abdominal infections. J Chemother 2009, 21(Suppl 1):3-4.
• [20]Weigelt JA: Empiric treatment options in the management of complicated intra-abdominal infections. Cleve Clin J Med 2007, 74(Suppl 4):S29-37.
• [21]Marshall JC, Innes M: Intensive care unit management of intra-abdominal infection. Crit Care Med 2003, 31(8):2228-37.
• [22]Herzog T, Belyaev O, Muller CA, et al.: Bacteribilia after preoperative bile duct stenting: a prospective study. J Clin Gastroenterol 2009, 43(5):457-62.
• [23]Roehrborn A, Thomas L, Potreck O, et al.: The microbiology of postoperative peritonitis. Clin Infect Dis 2001, 33(9):1513-9.
• [24]Montravers P, Gauzit R, Muller C, et al.: Emergence of antibiotic-resistant bacteria in cases of peritonitis after intraabdominal surgery affects the efficacy of empirical antimicrobial therapy. Clin Infect Dis 1996, 23(3):486-94.
• [25]Burnett RJ, Haverstock DC, Dellinger EP, et al.: Definition of the role of enterococcus in intraabdominal infection: analysis of a prospective randomized trial. Surgery 1995, 118(4):716-21. discussion 721-3
• [26]Seguin P, Laviolle B, Chanavaz C, et al.: Factors associated with multidrug-resistant bacteria in secondary peritonitis: impact on antibiotic therapy. Clin Microbiol Infect 2006, 12(10):980-5.
• [27]Swenson BR, Metzger R, Hedrick TL, et al.: Choosing antibiotics for intra-abdominal infections: what do we mean by "high risk"? Surg Infect (Larchmt) 2009, 10(1):29-39.
• [28]Seguin P, Fedun Y, Laviolle B, et al.: Risk factors for multidrug-resistant bacteria in patients with post-operative peritonitis requiring intensive care. J Antimicrob Chemother 2010, 65(2):342-6.
• [29]Falagas ME, Karageorgopoulos DE: Extended-spectrum beta-lactamase-producing organisms. J Hosp Infect 2009, 73(4):345-54.
• [30]Eagye KJ, Kim A, Laohavaleeson S, et al.: Surgical site infections: does inadequate antibiotic therapy affect patient outcomes? Surg Infect (Larchmt) 2009, 10(4):323-31.
• [31]Haddadin AS, Fappiano SA, Lipsett PA: Methicillin resistant Staphylococcus aureus (MRSA) in the intensive care unit. Postgrad Med J 2002, 78(921):385-92.
• [32]Cainzos M: Review of the guidelines for complicated skin and soft tissue infections and intra-abdominal infections--are they applicable today? Clin Microbiol Infect 2008, 14(Suppl 6):9-18.
• [33]Schneider CR, Buell JF, Gearhart M, et al.: Methicillin-resistant Staphylococcus aureus infection in liver transplantation: a matched controlled study. Transplant Proc 2005, 37(2):1243-4.
• [34]Hoban DJ, Bouchillon SK, Hawser SP, et al.: Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART). Antimicrob Agents Chemother 54(7):3031-4.
• [35]Pitout JD, Laupland KB: Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 2008, 8(3):159-66.
• [36]Barie PS, Christou NV, Dellinger EP, et al.: Pathogenicity of the enterococcus in surgical infections. Ann Surg 1990, 212(2):155-9.
• [37]Nichols RL, Muzik AC: Enterococcal infections in surgical patients: the mystery continues. Clin Infect Dis 1992, 15(1):72-6.
• [38]Chatterjee I, Iredell JR, Woods M, Lipman J: The implications of enterococci for the intensive care unit. Crit Care Resusc 2007, 9(1):69-75.
• [39]Sitges-Serra A, Lopez MJ, Girvent M, et al.: Postoperative enterococcal infection after treatment of complicated intra-abdominal sepsis. Br J Surg 2002, 89(3):361-7.
• [40]de Vera ME, Simmons RL: Antibiotic-resistant enterococci and the changing face of surgical infections. Arch Surg 1996, 131(3):338-42.
• [41]Yellin AE, Heseltine PN, Berne TV, et al.: The role of Pseudomonas species in patients treated with ampicillin and Sulbactam for gangrenous and perforated appendicitis. Surg Gynecol Obstet 1985, 161(4):303-7.
• [42]Szeto CC, Kwan BC, Chow KM, et al.: Recurrent and relapsing peritonitis: causative organisms and response to treatment. Am J Kidney Dis 2009, 54(4):702-10.
• [43]Taccone FS, Rodriguez-Villalobos H, De Backer D, et al.: Successful treatment of septic shock due to pan-resistant Acinetobacter baumannii using combined antimicrobial therapy including tigecycline. Eur J Clin Microbiol Infect Dis 2006, 25(4):257-60.
• [44]Blot S, De Waele JJ: Critical issues in the clinical management of complicated intra-abdominal infections. Drugs 2005, 65(12):1611-20.
• [45]Christou NV, Turgeon P, Wassef R, et al.: Management of intra-abdominal infections. The case for intraoperative cultures and comprehensive broad-spectrum antibiotic coverage. The Canadian Intra-abdominal Infection Study Group. Arch Surg 1996, 131(11):1193-201.
• [46]Inui T, Haridas M, Claridge JA, Malangoni MA: Mortality for intra-abdominal infection is associated with intrinsic risk factors rather than the source of infection. Surgery 2009, 146(4):654-61. discussion 661-2
• [47]Wacha H, Hau T, Dittmer R, Ohmann C: Risk factors associated with intraabdominal infections: a prospective multicenter study. Peritonitis Study Group. Langenbecks Arch Surg 1999, 384(1):24-32.
• [48]Nystrom PO, Bax R, Dellinger EP, et al.: Proposed definitions for diagnosis, severity scoring, stratification, and outcome for trials on intraabdominal infection. Joint Working Party of SIS North America and Europe. World J Surg 1990, 14(2):148-58.
• [49]Linden PK, Moellering RC Jr, Wood CA, et al.: Treatment of vancomycin-resistant Enterococcus faecium infections with quinupristin/dalfopristin. Clin Infect Dis 2001, 33(11):1816-23.
• [50]Ziglam H: Daptomycin and tigecycline: a review of clinical efficacy in the antimicrobial era. Expert Opin Pharmacother 2007, 8(14):2279-92.
• [51]Van Laethem Y, Sternon J: Linezolid (Zyvoxid). Rev Med Brux 2004, 25(1):47-50.
• [52]Hasper D, Schefold JC, Baumgart DC: Management of severe abdominal infections. Recent Pat Antiinfect Drug Discov 2009, 4(1):57-65.
• [53]Oliva ME, Rekha A, Yellin A, et al.: A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections [Study ID Numbers: 3074A1-301-WW; ClinicalTrials.gov Identifier: NCT00081744]. BMC Infect Dis 2005, 5:88. BioMed Central Full Text
• [54]Babinchak T, Ellis-Grosse E, Dartois N, et al.: The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin Infect Dis 2005, 41(Suppl 5):S354-67.
• [55]Fomin P, Beuran M, Gradauskas A, et al.: Tigecycline is efficacious in the treatment of complicated intra-abdominal infections. Int J Surg 2005, 3(1):35-47.
• [56]Sader HS, Jones RN, Dowzicky MJ, Fritsche TR: Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit. Diagn Microbiol Infect Dis 2005, 52(3):203-8.
• [57]Biedenbach DJ, Beach ML, Jones RN: In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant gram-positive blood stream infection isolates and strains producing extended-spectrum beta-lactamases. Diagn Microbiol Infect Dis 2001, 40(4):173-7.
• [58]Lee C: Therapeutic challenges in the era of antibiotic resistance. Int J Antimicrob Agents 2008, 32(Suppl 4):S197-9.
• [59]French GL: What's new and not so new on the antimicrobial horizon? Clin Microbiol Infect 2008, 14(Suppl 6):19-29.
• [60]Dupont H: The empiric treatment of nosocomial intra-abdominal infections. Int J Infect Dis 2007, 11(Suppl 1):S1-6.
• [61]Mazuski JE, Sawyer RG, Nathens AB, et al.: The Surgical Infection Society guidelines on antimicrobial therapy for intra-abdominal infections: evidence for the recommendations. Surg Infect (Larchmt) 2002, 3(3):175-233.
• [62]Sandiumenge A, Diaz E, Rodriguez A, et al.: Impact of diversity of antibiotic use on the development of antimicrobial resistance. J Antimicrob Chemother 2006, 57(6):1197-204.
• [63]Kumar A, Roberts D, Wood KE, et al.: Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006, 34(6):1589-96.
• [64]Krobot K, Yin D, Zhang Q, et al.: Effect of inappropriate initial empiric antibiotic therapy on outcome of patients with community-acquired intra-abdominal infections requiring surgery. Eur J Clin Microbiol Infect Dis 2004, 23(9):682-7.
• [65]Kumar A, Ellis P, Arabi Y, et al.: Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest 2009, 136(5):1237-48.
• [66]Bodmann KF: Complicated intra-abdominal infections: pathogens, resistance. Recommendations of the Infectliga on antbiotic therapy. Chirurg 2010, 81(1):38-49.
• [67]Sandiumenge A, Diaz E, Bodi M, Rello J: Therapy of ventilator-associated pneumonia. A patient-based approach based on the ten rules of "The Tarragona Strategy". Intensive Care Med 2003, 29(6):876-83.